Kansas City Life Insurance (KCLI) is a conservatively family-run company that has been in business for over a
hundred years.
The company does mostly life insurance and annunities with some
health insurance. It has paid $1.08 in annual dividends for the last two
decades. Currently it is trading at $37.65. So its
dividend yield is almost 3%, a full 50% higher than the 2% of the S&P500
as a whole.
I've added to my position significantly in the past two years
because of its attractive price to book ratio. In other
words, this is the classic 50 cent dollar.
During the market crash this spring, the market braced for a wave
of corporate defaults. Life insurance companies were considered
really vulnerable because of their large corporate bond holdings.
KCLI had $2.1B of investment grade corporate bonds out of $3.9B in investments on its
balance sheet. The stock cratered to $23 and
I feared the company was going under.
The yield on investment grade corporate bonds was usually a little over 2%, but it
doubled to almost 5% at the worst time of the crisis.
Thankfully, though,
the Fed pulled out all the stops and declared it was going to
purchase investment grade bonds to prop up the market.
Since that announcement in march and the massive market trough and peak,
the company's book value now is at its highest ever. The tangible book
value per share is $88, but the stock price is $37.65. Go figure!
The following chart shows the relationship of the book value per share
and the share price for the last 15 years. Note that right now
the spread between the book value and the price is the biggest ever.
I am simply hoping (or better yet praying) that this spread will
return more to "normal".
But how is it possible for a company to be this cheap in such a raging bull
market? There are some obvious explanations. This is a value stock which is very
much out of favor. The company is a private smallcap in a very boring industry.
It is also very much a value stock in a time when value is out of favour.
But I think
the most convincing reason for the depressed valuating on KCLI
is its poor earnings performance. The company
consistently earns no more than 4% on equity in the past
decade. I feel this is
in part the result of a very conservative investment strategy. The investments in
turn earn ever lower returns due to ever lower interest rates.
To illustrate,
the following chart shows the total annual insurance revenues and the dividend and interest income.
Note the underwriting is fine but income has steadily
declined. Note also that when company's book value appreciates
due to the big unrealized gains on investments. However, such appreciation is not counted
as regular earnings but as comprehensive income. Therefore, it
doesn't count as part of earnings per share.
So what to do with KCLI? Recently, I have leaned more towards diversification and
taking a more long term view of my holdings. I can afford
to be patient with safe companies like KCLI
because the company's dividend payout is about the same
as my borrowing costs. So, for now, I will just sit and wait for some
company surprise or market sentiment to change.
Lastly, before I conclude, I want to give a shot out to the provider
of tikr.com.
The website is the best fundamental research tool for the retail
investor that I've come across. It
provides very detailed financial data for every market worldwide going back 15
years. The above two charts was made possible with data
from the website. The site is beta and I am a trial user. If you want to be a beta
customer like me you can search around or contact the website.
Tuesday, December 29, 2020
Sunday, August 16, 2020
A Look at Senvest Capital
Senvest Capital is a company that I've discussed many times but not recently. Many
things have happened since I lost wrote about it. So, I am going to
review the company here.
Senvest Capital is well-known for being home to the Senvest Master Fund and the Senvest Technology Partner fund. The Mashaal family are majority owners of the company and these two funds are hedge funds managed by Richard Mashaal. This means that Richard Mashaal (through a company he owns) is the general partner. Senvest Capital is a limited partner in this enterprise. And there are also many LPs who are outside investors. The company also owns a lot of illiquid stuff like real estate, REITs, and private companies.
So by owning Senvest Capital, a shareholder actually downs several hedge funds and investments that the public don't normally cannot access.
So the pros and cons of buying this stock is, in principle, very simple. The stock trades at a tremendous discount to equity value — more about this later. And the investment management has an exceptional track record. However, on the negative side, the employee salaries and fees are very high, and they have never paid out dividends.
Another characteristic, which can be good or bad depending how you look at it, is that Senvest Capital's financial fortunes can be wild! The company earned CDN$(51.72) and CDN$39.16 per share in 2018 and 2019, respectively. And the first quarter 2020 has been a disaster, shareholders lost CDN$(129.38) per share! These are all due to the drop in market values of equities, be it realized or unrealized.
For the reset of this document I will refer to all amounts as Canadian dollars.
Senvest Capital promptly posts its monthly hedge fund resulte online. This gives us some idea of the company's performance. The Master fund lost 53% in Q1! No wonder its earnings were so bad. However, it has come back for Q2 and gained back half of the losses by August 1. The Senvest Technology fund was up 25% in Q2 and is positive for the year.
Just like Berkshire Hathaway, the main gauge of Senvest's stock value is the company's equity.
The company's stock should rise and fall proportionally with its equity. Senvest has traditionally traded at 60%-70% of equity. But the recent market drop has increased the discount significantly.
To illustrate the company's value, I have broken down the balance sheet into five components. The first is working capital. This is the safest part of the equity. Market conditions should not affect the value. The second component is the hedge fund portion of the company. The company consolidates the entire hedge fund value onto its balance sheet. So, it must also consolidate the amounts owed to the funds other partners as liability, as well as short positions. The third component comprises the illiquid assets including a lot of real estate, investments in private REITs and private companies. The company tends to put the illiquid investments onto its own books and more liquid investments into its hedge funds. The fourth component of the balance sheet includes assets and liabilities that don't fit in the above three categories. And the last componenent is the amount owed to Richard Mashaal as minority interest.
The following table shows the equity values of the five components at the end of 2019 and Q1 2020, the most recent balance sheet data. All values are thousands of CDN dollars.
So the bulk of the Q1 loss appears to be from the second components which is mostly the hedge funds. The equity value went from $818M to $496M. And we already saw that Q2 hedge fund numbers are much better. The other assets are either liquid and safe, or are illiquid assets which I just assume didn't change in value. So then, the company has a lot of equity that are not tied to hedge funds. Therefore, the company did not do nearly as badly as the hedge funds.
But note the extreme low stock value when compared with the equity. This is not a reasonable valuation. And I don't know the reason for it considering that this was the case at the start of 2020 before the coronavirus impacted the markets. But there is a long-held perception that the company insiders do not treat the minority shareholders fairly. Company insiders are excessively compensated. The company has just 32 employees and they were paid $35 M. That is an average of over $1M per employee!
On top of this, Richard Mashaal, the vice-president of the company, is also paid his fees for running the GP of the hedge funds. The hedge fund charges 1.5% of assets plus a 20% share of profits as management fees. Senvest Capital gets 60% of that fee for providing the infrastructure and employee resources for the hedge funds. But still, 40% goes to Richard Mashaal's company.
The company does not disclose how much it owns in the hedge funds. Instead it lumps all the hedge fund holdings together with its own holdings. The company does show the the external portion of the hedge funds as "Liability for redeemable units" Based on this, I can calculate that the Senvest Capital portion of the hedge funds is about 35%.
The accounting for the hedge funds' fees can be quite confusing, so I've broken it down into a table for clarity. The following table shows who pays the fees and who receives it.
So the Senvest Capital receives 39% from external partners and pays Richard Mashaal 14%. This means the company get a net 25% to pay employees salaries. In a down year where the only fee is the 1.5% of assets, one can see it is ony a few million, and that is only a tiny fraction of employee payroll. And even this amount is an overestimation of fees because $189M of assets owned by "employees" are exempt from fees.
On the other hand, Richard Mashaal gets 40% of the fees as minority interest, which was $5.2M in 2019!
Richard Mashaal has certainly been an incredible hedge fund manager. In his more than twenty years managing the funds, funds have grown from $5M to more than a billion under management. But Richard Mashaal and his father Victor already own more than 50% of Senvest Capital, and yet Richard still gets $1.7 M compensation from Senvest Capital, plus payments to him as minority interest.
In the end, there isn't much I can do as a tiny minority shareholder. I do not have the capital nor the time to be an activist. My cold calculation says that no matter the employee compensation, the company is a profitable enterprise in the long run. As such its assets, which are all investments, should not trade at 46% of equity, which is what it is trading at today. The current valuation is 55% off its peak a few years ago. To simply go back to 60% of equity, the shares will gain 33%. And I am confident it will happen sooner than later.
Senvest Capital is well-known for being home to the Senvest Master Fund and the Senvest Technology Partner fund. The Mashaal family are majority owners of the company and these two funds are hedge funds managed by Richard Mashaal. This means that Richard Mashaal (through a company he owns) is the general partner. Senvest Capital is a limited partner in this enterprise. And there are also many LPs who are outside investors. The company also owns a lot of illiquid stuff like real estate, REITs, and private companies.
So by owning Senvest Capital, a shareholder actually downs several hedge funds and investments that the public don't normally cannot access.
So the pros and cons of buying this stock is, in principle, very simple. The stock trades at a tremendous discount to equity value — more about this later. And the investment management has an exceptional track record. However, on the negative side, the employee salaries and fees are very high, and they have never paid out dividends.
Another characteristic, which can be good or bad depending how you look at it, is that Senvest Capital's financial fortunes can be wild! The company earned CDN$(51.72) and CDN$39.16 per share in 2018 and 2019, respectively. And the first quarter 2020 has been a disaster, shareholders lost CDN$(129.38) per share! These are all due to the drop in market values of equities, be it realized or unrealized.
For the reset of this document I will refer to all amounts as Canadian dollars.
Senvest Capital promptly posts its monthly hedge fund resulte online. This gives us some idea of the company's performance. The Master fund lost 53% in Q1! No wonder its earnings were so bad. However, it has come back for Q2 and gained back half of the losses by August 1. The Senvest Technology fund was up 25% in Q2 and is positive for the year.
Just like Berkshire Hathaway, the main gauge of Senvest's stock value is the company's equity.
The company's stock should rise and fall proportionally with its equity. Senvest has traditionally traded at 60%-70% of equity. But the recent market drop has increased the discount significantly.
To illustrate the company's value, I have broken down the balance sheet into five components. The first is working capital. This is the safest part of the equity. Market conditions should not affect the value. The second component is the hedge fund portion of the company. The company consolidates the entire hedge fund value onto its balance sheet. So, it must also consolidate the amounts owed to the funds other partners as liability, as well as short positions. The third component comprises the illiquid assets including a lot of real estate, investments in private REITs and private companies. The company tends to put the illiquid investments onto its own books and more liquid investments into its hedge funds. The fourth component of the balance sheet includes assets and liabilities that don't fit in the above three categories. And the last componenent is the amount owed to Richard Mashaal as minority interest.
The following table shows the equity values of the five components at the end of 2019 and Q1 2020, the most recent balance sheet data. All values are thousands of CDN dollars.
Aug 2020 | Q1 2020 | 2019 | |
---|---|---|---|
Working Capital | 29873.00 | 14284.00 | |
+ Equity investments and other holdings | 496424.00 | 818797.00 | |
+ Real Estate and Illiquid Assets | 125701.00 | 113107.00 | |
+ Other assets minus liabilities | 3750.00 | -3533.00 | |
- Non-controlling interests | 16374.00 | 23265.00 | |
= Shareholder Equity | 780000 (est) | 639374.00 | 919390.00 |
Shares | 2630.00 (est) | 2634.00 | 2652.00 |
BVPS | 296.58 | 242.74 | 346.68 |
Price | 135 | 110.00 | 172.25 |
PTBV | 0.46 | 0.45 | 0.50 |
So the bulk of the Q1 loss appears to be from the second components which is mostly the hedge funds. The equity value went from $818M to $496M. And we already saw that Q2 hedge fund numbers are much better. The other assets are either liquid and safe, or are illiquid assets which I just assume didn't change in value. So then, the company has a lot of equity that are not tied to hedge funds. Therefore, the company did not do nearly as badly as the hedge funds.
But note the extreme low stock value when compared with the equity. This is not a reasonable valuation. And I don't know the reason for it considering that this was the case at the start of 2020 before the coronavirus impacted the markets. But there is a long-held perception that the company insiders do not treat the minority shareholders fairly. Company insiders are excessively compensated. The company has just 32 employees and they were paid $35 M. That is an average of over $1M per employee!
On top of this, Richard Mashaal, the vice-president of the company, is also paid his fees for running the GP of the hedge funds. The hedge fund charges 1.5% of assets plus a 20% share of profits as management fees. Senvest Capital gets 60% of that fee for providing the infrastructure and employee resources for the hedge funds. But still, 40% goes to Richard Mashaal's company.
The company does not disclose how much it owns in the hedge funds. Instead it lumps all the hedge fund holdings together with its own holdings. The company does show the the external portion of the hedge funds as "Liability for redeemable units" Based on this, I can calculate that the Senvest Capital portion of the hedge funds is about 35%.
The accounting for the hedge funds' fees can be quite confusing, so I've broken it down into a table for clarity. The following table shows who pays the fees and who receives it.
Recipient | External Partners Fees (65%) |
Senvest Capital Fees (35%) |
---|---|---|
Senvest Capital Shareholder Equity (60%) | From: income, liabilities 39% | |
Minority Interest (40%) |
From: income, liabilities 21% |
From: income, shareholder equity 14% |
So the Senvest Capital receives 39% from external partners and pays Richard Mashaal 14%. This means the company get a net 25% to pay employees salaries. In a down year where the only fee is the 1.5% of assets, one can see it is ony a few million, and that is only a tiny fraction of employee payroll. And even this amount is an overestimation of fees because $189M of assets owned by "employees" are exempt from fees.
On the other hand, Richard Mashaal gets 40% of the fees as minority interest, which was $5.2M in 2019!
Richard Mashaal has certainly been an incredible hedge fund manager. In his more than twenty years managing the funds, funds have grown from $5M to more than a billion under management. But Richard Mashaal and his father Victor already own more than 50% of Senvest Capital, and yet Richard still gets $1.7 M compensation from Senvest Capital, plus payments to him as minority interest.
In the end, there isn't much I can do as a tiny minority shareholder. I do not have the capital nor the time to be an activist. My cold calculation says that no matter the employee compensation, the company is a profitable enterprise in the long run. As such its assets, which are all investments, should not trade at 46% of equity, which is what it is trading at today. The current valuation is 55% off its peak a few years ago. To simply go back to 60% of equity, the shares will gain 33%. And I am confident it will happen sooner than later.
Saturday, July 4, 2020
Why I Bought Altria, Again
My most old and familiar holding is Philip Morris. Altria (MO) is the
US version and Philip Morris International (PMI) is the
international version.
They are the famous makers of the Marlboro brand.
In a way these two companies are the simplest businesses to understand. They spit
out copious amounts of cash. And the majority of the cash goes to the government
coffers. At the same time
these governments want to ostensibly regulate the tobacco industry out of business.
And finally, people are generally smoking less than before. Today in the
US only 16% of the population smoke and the per capita consumption is 1/4
the number at the peak in 1960.
First, I'll discuss Altria. In the US the best selling
cigarette by far is Marlboro. It is 43% of the market!
In my table,
I have omitted the equity metrics because they have negative tangible book value.
That is not to say that these companies are not valuable.
It is just that their value is almost entirely
in their brand. Moreover,
these companies have enormous debt that is more than
tangible assets they have.
So their
investment utility is solely based on their dividends. And they
are very generous with dividends. Their pay ratios approach 100%.
But everyone knows
the future looks bleak for tobacco. But this has been the case for more than
20 years. In the last 10 years after Altria and PMI split into two companies, Altria
has increased dividends at a 9.5% rate! And today it yields 8.2%.
Somehow Altria has managed to increase profits when cigarette sales have
steadily declined consistently. Just last year US cigarette volume decreased 5.5%.
Because of Altria's simplicity, we can deduce its value simply from its cash flow
to shareholders. Imagine this plausible situation. Tobacco
consumption and regulation will drive companies like Altria to
bankruptcy in 30 years. But right now it is doing ok, and say it continues
to pay generous dividends and grow at 9.5% as the recent past for the next five years.
Then growth will taper. So for simplicity say dividend growth becomes
zero for five years. And
after that the dividend falls until zero 20 years later.
So what I described can be shown by the following chart.
The return from just the dividends is 8.3%!
Evaluating Altria using discounted cash flow (DCF) analysis would require
the cash return in this scenario to be greater than the risk-free return plus the risk premium.
In my analysis, I'd like to replace the risk-free rate with the cost to borrow money
to buy the stock. In today's low interest environment, this can be as low as 2%.
And a common risk premium is 6%. So therefore, I have a 8% hurdle for this investment,
which Altria just passed. And this is a very negative case scenario.
So Altria's cash flow can be worth the price today.
So putting the worse case aside, there are positive factors in Altria's future.
Cigarette consumption has declined consistently,
but
I think there is a limit. Society has clamped down on minors smoking and
smoking in public places. But for the hard-core smokers, nothing will deter
them. And taxation is already 45% of the current cigarette price. It is
primarily a business for the government! It is not
in the government's interest to kill cigarettes. This also means that companies like
Altria have big hidden pricing power. Altria gets less than 20% of each cigarette
sold, so when it increases the selling price by 10% the consumer only feels a 2% increase.
Also, some of the decline is due to the switch to new and old alternative products such as
e-cigarettes, smokeless tobacco and marijuana.
It is easy to see the appeal of a nicotine fix without the social stigma.
And marijuana does less damage to health than tobacco products.
Altria, has dabbled in all these areas. Altria is the leading US supplier of smokeless
tobacco products such as Copenhagen.
They bought a $13 B stake in JUUL Labs, a
e-cigarette maker. However, this deal was a disaster for the Altria and the
company has written off 2/3 of the investment.
And finally, the company has also tried to invest in marijuana through its
45% ownership of Cronos, a Canadian cannabis company. That hasn't worked out well either
as Cronos stock has dropped by 2/3 also!
Aside for tobacco and marijuana, Altria is also big into their sin companion:
alcohol.
Altria owns a small wine maker, and most importantly, a 10% stake in Anheuser-Busch InBev,
which is worth $18B.
The human race may get more and more health conscious, on average, but
I think there will always be a place for sin. We are living better and longer,
then we should also live it up more!
So,
over the long
term, I think that Altria may very well be able to hit on a killer product that
will replace cigarettes, if and when cigarettes are regulated to oblivion.
All these factors support my view that Altria and other tobacco companies are
underestimated companies with a large margin of safety and are well worth the
risk to invest. They are the quintessential value stocks.
MO | |
---|---|
Price | $39.1 |
Marketcap (M) | $72726 |
PE | 2019: (loss) 2018: 10.49 |
Div Yield (%) | 8.18 |
Tuesday, June 9, 2020
Update on My Insurance Holdings
Kansas City Life Insurance (OTC:KCLI) is a smallcap
life and health insurance company with a long and stable history.
In the company's Q1 earnings report their investments were down $38 M due to the market
downturn. Consequently
the company equity dropped $3 per share but
book value is still $81 per share.
KCLI makes 30% of its revenue from
investments, therefore investment income is critical to be profitable.
But in this low interest environment
the company must sacrifice safety to get decent yield.
The company
has more than half of its assets in corporate bonds. Virtually
all of its bonds are investment grade, but there is still a lot
at the bottom tier of investment grade.
When the downturn happened, there was a big fear that we would
see a wave of corporate downgrades and defaults.
Fortunately, the Fed pulled out the bazooka and said it was
willing to buy up corporate debt to shore up the market.
In the report, the company still has $779 M of equity, even
after factoring in Q1 losses.
That may seem like plenty but the company's capital and surplus (equity) for statutory regulation
purposes is only $260 M at 2019 year end. This $260 M amount is used by
regulators determine if the company is solvent and can do more business.
So a deep downturn in the bond market can be
very scary for the company. But they dodged a bullet, maybe, as the
bond market has been quite bullish recently.
KCLI is a really conservative old insurance company.
The Bixby family has run it for four generations! Philip Bixby CEO has run the company for
the last two decades. Because the company is so stable, past data can be very useful
to understand the company and its management intentions.
In the last 15 years,
their overall book value has gone from $692 M to $779 M.
Over the same period, their shares outstanding have gone from 11.9 M to 9.6 M, as
they have consistently tried to buy their shares back, mostly in the $40-$50 range.
So the net result is that
their book value per share has gone from $51 to $81 in 15 years.
That's a paltry 3.13% return.
Along with equity growth, shareholders also get a steady dividend.
Sadly, since the current CEO has taken over the company twenty years ago, they
have never increased the dividend, although one year, they did distribute
a special dividend of
$2 per share.
The stock is right now at $29.40 after the recent market drop, but at this level
it still
hasn't recovered like the favoured US large caps.
If the company could return to around $36, that is a 3% dividend.
Add the dividend to the 3.13% equity growth and
overall,
shareholders can expect around a 6.13% return.
This isn't a great return, but I just live with KCLI as a steady
source of income. If I have spare cash, I can put it to work at KCLI.
Or if I want to get adventurous, I could borrow money to buy KCLI. With interest
rates so low, I can pocket the spread between the dividend and the
interest cost.
My second insurance holding is European Reliance (ATH:EUPIC).
This company is similar to KCLI. It does life, health and auto insurance for the Greek
market.
EUPIC had a great 2019, the company earned € 17.5 M, and € 22.4 M pre-tax.
Of the pre-tax profit, € 7.3 M was from underwriting, and all other was € 15.1 M.
As expected however,
Q1 2020 was bad news. The company's book value dropped by € 13 M.
Again, it was better than I feared, because I saw that they have downside exposure to
€ 30 M of Greek mutual funds.
The ratios in the table are as of Q1 2020, so they still aren't bad.
If
that is the worst of it, EUPIC is a good company selling for really cheap.
And it is very generous with the dividends.
I added to my position during this downturn.
That's the second update of my holdings. Next post I will update my cigarette stocks.
KCLI | EUPIC | |
---|---|---|
Price | $29.4 | € 3.69 |
Marketcap M | $282.24 | € 101.47 ($ 114.97) |
ROE % | 2.6 | 11.8 |
PE | 14.11 | 6.55 |
PTBV | 0.36 | 0.78 |
Div Yield % | 3.67 | 6.5 |
Wednesday, June 3, 2020
Adding More Japanese Value Stocks
In the last entry I described my view that the way
to win in this market is to arbitrage across time and
markets.
I've described here that right now the US largecap market is the
most overpriced ever.
But many overseas markets are reasonable. I am quite heavily invested in
Japan and South Africa. I feel quite strongly the coming decade is
going to be all about emerging markets and value stocks.
Japan is a value country. It is a very developed
country that has been heavily discounted for a generation. But, whereas
in previous times Japanese companies mainly disregarded the minority
shareholders, now they are much more generous. One
can find dozens and dozens of companies that pay more than 3% dividends,
and are growing dividends around 10%.
Yes, the persistent explanation for stocks being so cheap is the aging population
and their ballooning debt. But look at the US. Their debt is getting
up there, and the dollar is stronger than ever.
And the same goes for the euro.
In March this year, the US market fell 35% off the peak.
And I took the opportunity to add to my Japanese holdings. The table here shows
the four stocks I currently own. The latter two I have had for
7 years. Both are up more than 3x when factoring in dividends.
I also added two new stocks. My main criteria
are
San | Takamatsu | Tachibana | Riken | |
---|---|---|---|---|
Price | ¥ 1234 | ¥617 | ¥ 1760 | ¥2402 |
Marketcap (M) | ¥ 13820.80 ($ 127.38) | ¥ 6663.60 ($ 61.42) | ¥ 45760.00 ($ 421.75) | ¥ 56687.20 ($ 522.46) |
ROE % | 6.8 | 9 | 6.3 | 8.7 |
PE | 7.45 | 4.71 | 10.42 | 13.78 |
PTBV | 0.51 | 0.42 | 0.66 | 1.27 |
Div Yield % | 2.59 | 4.05 | 2.73 | 1.67 |
P/NCAV | ‐ | 0.6 | 0.71 | ‐ |
- little or no debt
- high dividend yield
- growing dividends
- low PE
Saturday, May 30, 2020
How Do We Beat the Market?
It's been two months since my last post when the coronavirus really became the world's
biggest problem. Back then, people were saying life will never be same, the world will hit a recession
worse than the great depression, and on and on.
To me what people are saying is not necessarily wrong, but it is the peoples tone that
I focus on. The media is having a field day with this. Their job is to maximize
their views or sell their papers and magazines. They will emphasize the
worst news over and over because it gets people's attention and hence sells.
After a long period of this blanket coverage, it
cloud peoples judgement.
And the key to successful investment is good judgement, even though
investment has a huge luck component.
When an investor's judgement is clouded they can seriously lose. An
investor whose judgement is not affected can win. Or to put it more bluntly,
the latter can take advantage of the former.
And the latter group consists of the great investors. They are
coming out of the woodwork to make some serious money. Among them are
Paul Ichan and Bill Ackman.
These people made bets against the market, against the coronavirus.
And they succeeded not because they were lucky but because
they noticed their bets had huge risk/reward ratios and
they had the guts to act on it.
One can easily google their names and
see their recent interviews on Youtube. I found them
highly informative and recommend others to watch.
Back in the 50s in Buffett's heyday when Buffett made 30 plus percent every year, his
secret
was find individual cheap stocks from
the Moody's Manual. That was an edge back then because
it is hard to read through several thousand pages of three-column
text and numbers.
And he did it twice! Today that doesn't work, because all such information
is digitized. So one can simply use screeners or write their own code to
do what Buffett did much faster and for much more stocks. Plus
Buffett has already spread the gospel of value investing, so his secret
is out.
Because of these two factors,
I heard many people suggest that
the stock market is more efficient today than before.
I vehemently disagree.
Take a look at the following log graph of the
S&P 500 (at top). The economy and market grow exponentially, so the trendline should be a straight
line. When gods are the only participants in the market I guess the S&P500 should also be a straight line,
because gods have perfect information.
But since the stock market participants are mortals with limited information, the graph is not
smooth. That doesn't mean the market is not efficient.
Next, we can look at two different time periods, one contemporary and one from the past.
The second graph show the index over the last 40 years. And the third graph show the index in the period covering the two world
wars, including the great depression.
If the market is more efficient today than earlier times then
it should show in differences between the second and third graph.
But looking at graph two and three it isn't clear that one is more volatile than the other. We have had massive peak to trough moves around 1989, 2000 and 2008.
Just as we had them in the 1910 panic and the great depression.
So I can argue the market is not any less volatile than earlier years! So the market has been and still is inefficient. But how can we take
advantage of this inefficiency. I already stated that stock picking is harder today than
in Buffett's early years. Well, the market is inefficiency today simply
because
all good American companies are expensive.
Take Microsoft for example. In the last 7 years the stock price has gone
up by approximately 7x. Meanwhile its earnings has only doubled!
Compare this with Tachibana Electech (TSE:8159), in the 7 years that I have held it the stock has
gone up 2.5x but its earnings also doubled.
And while Microsoft is selling at 30x earnings, Tachibana is selling at 10x earnings.
And I know different people will say that this anomaly is justified in different ways. I can
guess some of the reasons:
- the investors don't care about earnings and value
- the investors believe in America but don't believe in foreign currencies and foreign economies
- the cheaper company is more likely to be a fraud
- future growth will justify it.
Sunday, March 15, 2020
People, Let's get a Grip!
Happy Sunday everyone. I just had to get that out of the way!
The hysteria around where I am, is almost laughable. People are hoarding toilet
paper like it will give them immunity to Coronavirus! So, get a grip!
So, I am thinking that if people hoard toilet paper as a gut reaction to a virus, then certainly
everyday retail investors are capable of selling way beyond what the current situation calls for.
Unfortunately for me, I own a lot of lower-tier stocks, stocks that are in emerging markets and the
cheaper stocks in developed markets. So my stocks have actually dropped farther than the market
as a whole.
Below are four of my holdings. Notice that they all yield dividends way above average.
All four of these companies have improved earnings.
All four of these companies have increasing earnings.
Tachibana Electech (8159:TSE) is in
fact is a netnet. This means that it is worth more dead than alive! While I do realize that the
coronavirus crisis will materially impact Tachibana Electech — the company issued a profit warning for the current
quarter — nothing that happens this year should take 35% off the valuation!
I am posting this table to share and also to remind myself that we shouldn't pay
attention to the markets because the fundamentals reflect the value of
shares, not the market whims.
While we always suspect the market is due to get a shock that will cause a drop, where the shock
comes from is near impossible to guess with any certainty.
I never thought that when the 10 year run ends, the shock would
come not from geopolitical or world economic events, but from a
germ!
In 2009 when the world was suffering a financial meltdown, I read up on the great depression, and tried to
draw parallels. I found there weren't that many similarities.
Now in 2020, the world seemingly is going through a cataclysmic pandemic, I think it pays to read up on similar pandemics
of recent history. The table here shows the most deadly flu outbreaks during the last 150 years when we've had sophisticated financial
markets. In that time, I can safely say that these worldwide health crises have not had a negative impact on world economic growth. World War I and
the 1918-1919 influenza pandemic did not prevent the roaring twenties. The two pandemics in the 50's and 60's did not affect Warren Buffett's generation
in the least bit.
Sure, the world economic output could be reduced significantly because of the Coronavirus, but probably only for two quarters. China, the vanguard in this crises,
is already starting to stabilize its new infection rates. I wouldn't be surprised if things go back to 3-6 months there. And my feeling
is the lessons learned when this crises is over will spur new economic activity in the health care and infrastructure sector to
prepare for the next one. Also, lost production can be recovered when the world consumer market returns back to normal.
But many in the world will not try to rationalize the situation and instead make a sport of hoarding toilet paper and other necessities.
It is in our human nature to do something active when danger is lurking and is out of our control. And really there is no harm in doing so. However,
the same mentality cannot apply to retail investing, because the market will be rational in the end.
Today, the S&P 500 is down 25% from the peak because of a germ. I think this is definitely the time to be contrarian like Baron Rothschild, who famously said:
"Buy when there's blood in the streets, even if the blood is your own.".
Lewis | Tachibana | Riken | EUPIC | |
---|---|---|---|---|
Price | R 23.81 | ¥ 1248.00 | ¥ 1770.00 | € 3.38 |
Shares (M) | 80.3 | 26 | 23.6 | 27.5 |
Earnings TTM | 398.1 | 4422 | 3857 | 10.9 |
Marketcap (M) | R 1911.94 ($ 117.30) | ¥ 32448.00 ($ 306.11) | ¥ 41772.00 ($ 394.08) | € 92.95 ($ 103.17) |
ROE | 8.3 | 6.3 | 8.3 | 8.3 |
PE | 4.8 | 7.3 | 10.8 | 8.5 |
PTBV | 0.43 | 0.46 | 0.96 | 0.79 |
Div Yield | 10.46 | 3.85 | 2.2 | 3.85 |
Price / NCAV | - | 0.73 | 1.36 | - |
Fatalities | % of World | 1918 Flu | 50 M | 3 | 1958 Asian Flu | 2 M | 0.06 | 1962 Hong Kong Flu | 50 M | 0.03 | 2020 Coronavirus | 10,000 so far | 0.0001 |
---|
Wednesday, March 11, 2020
My Views on IEH Corp
Hi all, in the last year since I've been mostly silent, I've received the most inquiries about IEH Corp (OTC:IEHC). I have attended a number of the annual shareholder meetings and today I am going to give an update on how I see things. Note: the text below are
my impressions and opinions and recollection of conversations, take everything in here with a grain of salt. And with that out
of the way, let's dive in.
My impression from the meetings generally aligns with the market perception. The company is hitting a very good spot and things are generally on the up and up. Just look at the last seven years' revenue numbers below.
The CEO though, constantly reminds us that their customers are long-term customers and they are slow adopters. This means that it takes a long time to bag a new customer but when they do they stay as customers. A new customer must design in these hyperboloid connectors, and once they do they are hard to substitute.
So, sales improvement in this company take time. And one can expect more years of revenue increase. That said, there is also a limit to how much the company can sell. This is not a company making technological breakthroughs. Instead, it is a niche provider riding on society's increasing reliance on technology in more and more rough and extreme environments. Their technology is not new, in fact it is old enough to be out of patent protection.
Their main customers are the big drivers of our economy: defense, old and gas, commercial aerospace and the medical field. So long as the S&P 500 does well, so will the company, provided it can execute.
And execution is the main thing I am monitoring during my yearly visits. The company of course, has a very long history with a single family, the Offermans, as owner-operators. Recently, the fourth generation of the family has taken the helm. I am very pleased with this change. The current CEO, David Offerman, has taken the helm for three years. In that time, I just feel things look better to us shareholders. Firstly, the governance wasn't impressive, their non-executive board members did not even reside near the company and dialed into every board meeting. With some shareholder prodding, they have added more conventional and local people for board members.
The previous CEO, Michael Offerman, had also relied on a small-time accounting firm to do their books and inventory. This firm was replaced by a related accountant who was also a small operator. Last year, that accountant left. Incidentally, that second accountant attended the last shareholder meeting to tell everyone that it was all an amicable break. As I remember, he said that he liked the job but in the end he felt that he was too small to handle the task. And so, we are here today with a more traditional firm Marcum LLP as accountants.
Shareholders in past meetings have also expressed concerns when retained earning for grew several quarters as IEH had good numbers, but the value all just went to more inventory, instead of more cash. Furthermore, in the last meeting one shareholder pointed out that the company wrote off $400k in inventory for 2019, whereas was it was only $200k for 2018. So many shareholders are looking at the inventory and pressing for improvement.
On the positive side, in the last shareholder meeting I heard that the company was moving to SAP software. I also noticed the company hired a new, and much younger, controller. And the new controller just happens to specialize in SAP. I would expect that with this and the accounting changes we will see improvements in inventory controls and hence better margins.
So with the new CEO in this fourth year, I am watching for inventory levels and margins. My best scenario is that inventory stays flat and there are no significant write-offs, and margins continue to improve. The CEO used to be in charge of sales and clearly has done a great job in the sales department. By showing better control of inventory and margins he will be able to keep up the earnings growth. In the last seven years that I have owned this stock, I have seen annual EPS go from $0.63 to $2.15. Of course, as most people know, the unusual spike in sales last year was due to a single customer order. That customer had decided to switch to hyperboloid from a cheaper technology. But no single customer contributes more than 14% of revenue, so even if this customer cut off all future orders, the company is still growing at a goodly pace.
The previous year spike also contributed significantly to operating margins. The operating margin
for the last five years are 20%, 16%, 14%, 19% and 27% in 2019. Other than the previous year,
the company has never achieved margins over 20%. If the company can be a bit more consistent and keep the margin
say, at 23%. I would feel confident that things have really changed to take this company to the next level;
the CEO has indicated that he wants to take the company back on to the Nasdaq someday.
And so, having weighted all these thoughts, I feel that the company at $17.40 today is about fairly priced. I know the stock was at a high of $25, reflecting the rich valuations of stocks everywhere. But I feel IEHC has to have another good year, maybe not as good as 2019, to deserve a price over $20. That said I did not sell at $25 because there is just too much upside. Like I said earlier, one really has to be patient with this stock. And if the stock drops under the $14 - $13 range, I definitely will start buying more. At $12, I would back up the truck!
My impression from the meetings generally aligns with the market perception. The company is hitting a very good spot and things are generally on the up and up. Just look at the last seven years' revenue numbers below.
The CEO though, constantly reminds us that their customers are long-term customers and they are slow adopters. This means that it takes a long time to bag a new customer but when they do they stay as customers. A new customer must design in these hyperboloid connectors, and once they do they are hard to substitute.
So, sales improvement in this company take time. And one can expect more years of revenue increase. That said, there is also a limit to how much the company can sell. This is not a company making technological breakthroughs. Instead, it is a niche provider riding on society's increasing reliance on technology in more and more rough and extreme environments. Their technology is not new, in fact it is old enough to be out of patent protection.
Their main customers are the big drivers of our economy: defense, old and gas, commercial aerospace and the medical field. So long as the S&P 500 does well, so will the company, provided it can execute.
And execution is the main thing I am monitoring during my yearly visits. The company of course, has a very long history with a single family, the Offermans, as owner-operators. Recently, the fourth generation of the family has taken the helm. I am very pleased with this change. The current CEO, David Offerman, has taken the helm for three years. In that time, I just feel things look better to us shareholders. Firstly, the governance wasn't impressive, their non-executive board members did not even reside near the company and dialed into every board meeting. With some shareholder prodding, they have added more conventional and local people for board members.
The previous CEO, Michael Offerman, had also relied on a small-time accounting firm to do their books and inventory. This firm was replaced by a related accountant who was also a small operator. Last year, that accountant left. Incidentally, that second accountant attended the last shareholder meeting to tell everyone that it was all an amicable break. As I remember, he said that he liked the job but in the end he felt that he was too small to handle the task. And so, we are here today with a more traditional firm Marcum LLP as accountants.
Shareholders in past meetings have also expressed concerns when retained earning for grew several quarters as IEH had good numbers, but the value all just went to more inventory, instead of more cash. Furthermore, in the last meeting one shareholder pointed out that the company wrote off $400k in inventory for 2019, whereas was it was only $200k for 2018. So many shareholders are looking at the inventory and pressing for improvement.
On the positive side, in the last shareholder meeting I heard that the company was moving to SAP software. I also noticed the company hired a new, and much younger, controller. And the new controller just happens to specialize in SAP. I would expect that with this and the accounting changes we will see improvements in inventory controls and hence better margins.
So with the new CEO in this fourth year, I am watching for inventory levels and margins. My best scenario is that inventory stays flat and there are no significant write-offs, and margins continue to improve. The CEO used to be in charge of sales and clearly has done a great job in the sales department. By showing better control of inventory and margins he will be able to keep up the earnings growth. In the last seven years that I have owned this stock, I have seen annual EPS go from $0.63 to $2.15. Of course, as most people know, the unusual spike in sales last year was due to a single customer order. That customer had decided to switch to hyperboloid from a cheaper technology. But no single customer contributes more than 14% of revenue, so even if this customer cut off all future orders, the company is still growing at a goodly pace.
IEHC | |
---|---|
Price | 17.40 |
Shares (M) | 2.32 (2.74 fully diluted) |
Equity (M) | 26.20 |
Earnings TTM | 3.71 |
Marketcap (M) | 40.60 |
ROE | 14.1 |
PE | 10.9 |
PTBV | 1.55 |
And so, having weighted all these thoughts, I feel that the company at $17.40 today is about fairly priced. I know the stock was at a high of $25, reflecting the rich valuations of stocks everywhere. But I feel IEHC has to have another good year, maybe not as good as 2019, to deserve a price over $20. That said I did not sell at $25 because there is just too much upside. Like I said earlier, one really has to be patient with this stock. And if the stock drops under the $14 - $13 range, I definitely will start buying more. At $12, I would back up the truck!
Subscribe to:
Posts (Atom)